SRDAN VERSTOVSEK to Early Termination of Clinical Trials
This is a "connection" page, showing publications SRDAN VERSTOVSEK has written about Early Termination of Clinical Trials.
Connection Strength
0.457
-
Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leuk Res. 2014 Mar; 38(3):316-22.
Score: 0.457
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.